Log in

NASDAQ:MDGL - Madrigal Pharmaceuticals Stock Price, Forecast & News

$117.20
+3.00 (+2.63 %)
(As of 12/8/2019 10:55 AM ET)
Today's Range
$113.97
Now: $117.20
$117.94
50-Day Range
$86.42
MA: $100.20
$117.35
52-Week Range
$82.31
Now: $117.20
$148.18
Volume78,091 shs
Average Volume124,546 shs
Market Capitalization$1.81 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.15
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MDGL
CUSIP87162T20
Phone267-824-2827

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$30.99 per share

Profitability

Net Income$-32,810,000.00

Miscellaneous

Employees17
Market Cap$1.81 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive MDGL News and Ratings via Email

Sign-up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.


Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions

What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) announced its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.03. During the same quarter in the previous year, the company earned ($0.56) EPS. View Madrigal Pharmaceuticals' Earnings History.

When is Madrigal Pharmaceuticals' next earnings date?

Madrigal Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Madrigal Pharmaceuticals.

What price target have analysts set for MDGL?

9 Wall Street analysts have issued twelve-month target prices for Madrigal Pharmaceuticals' shares. Their forecasts range from $126.00 to $215.00. On average, they expect Madrigal Pharmaceuticals' stock price to reach $158.17 in the next year. This suggests a possible upside of 35.0% from the stock's current price. View Analyst Price Targets for Madrigal Pharmaceuticals.

What is the consensus analysts' recommendation for Madrigal Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Madrigal Pharmaceuticals.

What are Wall Street analysts saying about Madrigal Pharmaceuticals stock?

Here are some recent quotes from research analysts about Madrigal Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-ß agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-ß agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania. " (10/9/2019)
  • 2. HC Wainwright analysts commented, "We are confident that the MAESTRO-NASH trial is well-managed: it is conducted by PRA Health Sciences (private), a top CRO that was awarded the 2019 CRO a top drawer group of clinical site investigators including principal investigator Dr. Antonio, TX. Importantly, MAESTRO-NASH’s 52-week treatment period was selected in order to optimize patient compliance and the repeat biopsy rate, as both drop off considerably in trials that last more than one year." (7/3/2019)
  • 3. Stifel Nicolaus analysts commented, "We believe resmetirom’s Phase 2b data are encouraging on NASH resolution and emerging evidence continues to point to the possibility resmetirom could demonstrate a benefit on fibrosis over time. We are positively biased heading into Phase 3 however; we see few company specific catalysts to drive shares upward in the next ~12-18 months and think the stock could be volatile around updates from competitors (i.e. VKTX, GNFT, etc.) – this leads to our Hold rating. Ultimately, we feel MDGL will largely remain range bound before it reports Phase 3, 52-week data in 2H21 and based on our diligence for our NASH white paper (link here), we suspect any strategic acquirer would want to confirm resmetirom’s safety/efficacy profile and gain some commercial validation for the NASH category, as a whole, before paying a large price tag for MDGL. So a near-term takeout is unlikely, in our view." (6/24/2019)

Has Madrigal Pharmaceuticals been receiving favorable news coverage?

News articles about MDGL stock have trended extremely negative recently, InfoTrie reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Madrigal Pharmaceuticals earned a coverage optimism score of -5.0 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Madrigal Pharmaceuticals.

Who are some of Madrigal Pharmaceuticals' key competitors?

What other stocks do shareholders of Madrigal Pharmaceuticals own?

Who are Madrigal Pharmaceuticals' key executives?

Madrigal Pharmaceuticals' management team includes the folowing people:
  • Dr. Paul A. Friedman, Chairman & CEO (Age 76)
  • Dr. Rebecca A. Taub, Founder, Exec. VP of R&D, Chief Medical Officer and Director (Age 67)
  • Mr. Marc R. Schneebaum, Sr. VP & CFO (Age 65)
  • Mr. Thomas W. Hare, Sr. VP of Clinical Management

Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (3.26%), Alps Advisors Inc. (0.20%), Point72 Asset Management L.P. (0.20%), Rhenman & Partners Asset Management AB (0.19%), SG Americas Securities LLC (0.15%) and Millennium Management LLC (0.12%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc, Fred B Craves, Marc R Schneebaum, Paul A Friedman and Rebecca Taub. View Institutional Ownership Trends for Madrigal Pharmaceuticals.

Which institutional investors are selling Madrigal Pharmaceuticals stock?

MDGL stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Point72 Asset Management L.P., Rhenman & Partners Asset Management AB, Alps Advisors Inc. and Barclays PLC. View Insider Buying and Selling for Madrigal Pharmaceuticals.

Which institutional investors are buying Madrigal Pharmaceuticals stock?

MDGL stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, California Public Employees Retirement System, Millennium Management LLC, Squarepoint Ops LLC, Mackay Shields LLC, Shikiar Asset Management Inc., Tower Research Capital LLC TRC and Metropolitan Life Insurance Co NY. Company insiders that have bought Madrigal Pharmaceuticals stock in the last two years include Fred B Craves and Paul A Friedman. View Insider Buying and Selling for Madrigal Pharmaceuticals.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $117.20.

How big of a company is Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals has a market capitalization of $1.81 billion. The biopharmaceutical company earns $-32,810,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. Madrigal Pharmaceuticals employs 17 workers across the globe.View Additional Information About Madrigal Pharmaceuticals.

What is Madrigal Pharmaceuticals' official website?

The official website for Madrigal Pharmaceuticals is http://www.madrigalpharma.com/.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at 267-824-2827 or via email at [email protected]


MarketBeat Community Rating for Madrigal Pharmaceuticals (NASDAQ MDGL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  361 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  626
MarketBeat's community ratings are surveys of what our community members think about Madrigal Pharmaceuticals and other stocks. Vote "Outperform" if you believe MDGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel